Featured Research

from universities, journals, and other organizations

Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals

Date:
October 22, 2008
Source:
Cardiovascular Research Foundation
Summary:
New research shows a low number of strokes and cardiac events in patients who had stents implanted utilizing a new embolic neuroprotection system during carotid stenting with commercial stents.

Results of a study on the use of the FiberNet® Embolic Protection System in carotid artery stenting were reported today during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The research showed a low number of strokes and cardiac events in patients who had stents implanted utilizing a new embolic neuroprotection system during carotid stenting with commercial stents.

Subbarao Myla, MD, Medical Director CV Research and Vascular Intervention, Hoag Memorial Hospital, Newport Beach, Calif. presented the results of "EPIC: Evaluating the Use of the FiberNet® Embolic Protection System in Carotid Artery Stenting." The study looked at patients who were at high risk for CEA that were treated with the FiberNet® Embolic Protection System during carotid artery stenting procedures. The data was compiled into a registry that tracked 237 patients at 26 sites across the U.S.

The system uses a unique filter design with low porosity and, according to Dr. Myla, "Its easy-to-use features combined with aspiration prior to retrieval lead to low event rates. The FiberNet system allows blood flow during the procedure, a fiber-based filter captures particles as small as 40 µm and the stent is delivered for placement using a standard coronary guide wire."

In the study, patients at high-risk for CEA were treated in a prospective, multi-center, non-randomized trial. The demographic profile of study participants included patients of mean age 73.9± 8.3 (ranging from 46-89), 21.1% were octogenarians, 62.4% were male, 20.3% were symptomatic, 39.7% had diabetes and 22.2% were current smokers.

Key exclusion criteria included planned treatment of contra-lateral carotid within 30 days, stroke within 48 hours, myocardial infarction (MI) within 14 days, total occlusion, stenosis unsuitable for carotid stenting and serial lesions that require more than one stent.

The EPIC study revealed very low stroke, MI and death rates using the FiberNet embolic protection system during carotid stenting. Further, the low porosity filter and ease of use combined with aspiration prior to retrieval led to low event rates. The 30-day event rates showed deaths constituted 0.4% of all strokes 2.1% (major stroke ─ 1.3% and minor stroke ─ 0.9%) and all myocardial infarctions at 0.9%. The 30 day composite primary endpoint for all events was 3.0%

Procedural results included a 97.5% technical success rate, 94.1% FiberNet device success, 100% two-wall vessel apposition and 90.9% visible debris captured.


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals." ScienceDaily. ScienceDaily, 22 October 2008. <www.sciencedaily.com/releases/2008/10/081016162251.htm>.
Cardiovascular Research Foundation. (2008, October 22). Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2008/10/081016162251.htm
Cardiovascular Research Foundation. "Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals." ScienceDaily. www.sciencedaily.com/releases/2008/10/081016162251.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) — Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) — According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) — The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins